Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer
Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3
The addition of nintedanib to docetaxel has a proven survival benefit as a second-line treatment following chemotherapy in a broad population of lung adenocarcinoma patients.4 However, data are scarce regarding the efficacy and safety of nintedanib in adenocarcinoma patients who have been pre-treated with chemotherapy as well as ICIs.
The results support a recent update to the ESMO guidelines around the treatment of NSCLC, which now recommend nintedanib in combination with chemotherapy as a second-line treatment following prior chemotherapy +/- ICIs.2 A recent report by Jesus Corral et al (WCLC, 2017) which evaluated nintedanib in combination with docetaxel in a similar setting showed similar efficacy and safety information.3
Professor Christian Grohé, Department of Respiratory Diseases, ELK Berlin, said: “As immunotherapy becomes the first-line treatment of choice in advanced lung adenocarcinoma, it’s important to have effective and safe treatment options following immunotherapy. The results from VARGADO provide important evidence supporting the use of nintedanib following initial treatment with immunotherapy and are in line with the recent update to the ESMO guidelines.”
Dr Victoria Zazulina, Global Head of Solid Tumour Oncology, Medicine at Boehringer Ingelheim, said: “With a devastating disease like lung cancer, every option matters. Today’s results provide evidence that nintedanib, when added to docetaxel, is a good therapeutic option for patients that progress following treatment with immunotherapy.”
~ENDS~
Please click on the link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/vargado-data
For more information, please visit: www.boehringer-ingelheim.com
Further Media Channels
www.facebook.com/boehringeringelheim
www.twitter.com/Boehringer
www.youtube.com/user/boehringeringelheim
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181214005105/en/
Contact information
Boehringer Ingelheim
Corporate Communications
Media
+ PR
Julia Faaß
Tel.: +49 (6132) 77-95614
Mobil: +49
(151) 15023438
Fax: +49 (6132) 77-6601
Email: press@boehringer-ingelheim.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Winka Dubbeldam Appointed Director and CEO of SCI-Arc28.4.2025 21:50:00 EEST | Press release
The Southern California Institute of Architecture (SCI-Arc) is thrilled to share that Prof. Winka Dubbeldam has been appointed as the next Director and Chief Executive Officer of SCI-Arc. A globally recognized Dutch architect, educator, and leader in design innovation, Winka will officially assume the role on September 1, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428994100/en/ Winka Dubbeldam Winka brings more than three decades of experience to the forefront of architectural practice and education. She is a full Professor of Architecture and served as Chair at the University of Pennsylvania Stuart Weitzman School of Design for ten years (2013–2023). Previously she initiated and directed the Post-Professional Architecture program for ten years (2003–2013), providing international students with innovative design skills, cutting-edge theoretical and technological knowledge necessary for a productive and innovativ
NIQ announces global data collaboration with The Trade Desk to enhance audience targeting28.4.2025 20:37:00 EEST | Press release
NIQ, a leading consumer intelligence company, today announced a strategic global collaboration with The Trade Desk, a global leader in advertising technology. The collaboration will integrate NIQ's consumer intelligence and global insights on shopping behaviors into The Trade Desk’s platform, supporting marketers to plan and activate ad campaigns more accurately. These new-to-market audiences, now available on The Trade Desk's media buying platform, will enable advertisers to reach their desired audiences in global markets, with effectiveness and precision. "Our collaboration with The Trade Desk represents a significant step forward in our mission to provide actionable insights across the advertising industry, at a global scale," said Joshua Pisano, Global Head of Product, Media at NIQ. "By integrating NIQ’s advanced audiences into The Trade Desk’s leading data marketplace, we are empowering advertisers with new data assets that provide more effective ad targeting and drive better mark
Actus Nutrition Acquires Protein Facility from Foremost Farms USA28.4.2025 20:30:00 EEST | Press release
Actus Nutrition (“Actus”), a leading vertically-integrated nutritional ingredients manufacturer and portfolio company of Butterfly Equity (“Butterfly”), today finalized an agreement to purchase a 99,000 sq. ft. processing facility from Foremost Farms USA (“Foremost Farms”). The facility, located in Sparta, WI, currently manufactures whey protein products, which Actus will continue producing at the location. As part of the deal, Actus and Foremost Farms will begin a long-term exclusive, network wide whey protein partnership supporting growth for both organizations. Actus plans to invest significant capital into the facility to increase capacity and expand its capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428226854/en/ Sparta, WI Facility “We’ll be able to hit the ground running because we can plug the Sparta facility into our existing manufacturing network without a lot of changes,” said David Lenzmeier, CEO
Al Zorah Announces Partnership with Four Seasons to Open a Luxury Beachfront Resort in Al Zorah, Ajman in 202628.4.2025 19:40:00 EEST | Press release
Al Zorah Development Company, a partnership between the Government of Ajman and Solidere International, together with Four Seasons, have announced plans to open Four Seasons Resort Ajman at Al Zorah in 2026. The beachfront luxurious resort will undergo extensive upgrades to the existing property, including upgrades to accommodation and public facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428436866/en/ From left: George Saad, CEO of Al Zorah Development Company, and Adrian Messerli, Area President, Hotel Operations, EMEA at Four Seasons, during the signing of the agreement. (Photo: AETOSWire) The resort will feature 23 villas, 74 rooms, and suites, all equipped with private terraces offering stunning views of the Arabian Gulf. Located just 25 minutes from Dubai International Airport, the resort offers a unique blend of comfort and natural tranquility. George Saad, CEO of Al Zorah Development Company, expressed
Essendi: A New Identity to Foster Responsible Leadership in European Hospitality28.4.2025 19:30:00 EEST | Press release
AccorInvest is changing its name and becoming Essendi. This change completes the transformation initiated in 2020 to make Essendi the European leader in responsible hospitality. This new identity embodies the group's ambition: to actively contribute to a more sustainable and higher-performing hotel industry. Since 2020, Essendi has embarked on an ambitious transformation, aiming to consolidate its leadership in Europe, strengthen its overall performance and integrate ESG criteria at the heart of its strategy. The group has refocused its portfolio on the most profitable assets in Europe, in the economy and mid-range segments, while optimizing the value of its hotels through dynamic asset management. The value of its portfolio was assessed at €7.8 billion as of December 31, 2024. This strategy, combined with a hybrid economic model, combining operational and real estate performance, enabled Essendi to achieve record results in 2024: revenue of €4.0 billion (+3.1% like-for-like vs. 2023)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom